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Abstract
Background: Polymorphisms of the vitamin D receptor (VDR) gene have been linked to both multiple sclerosis
(MS) and osteoporosis. We examined the frequency of the Taq-I and Bsm-I polymorphisms of the vitamin D
receptor (VDR) gene in 69 patients with MS and 81 age and sex-matched healthy individuals. Genotyping of Taq-I
(rs731236) and Bsm-I (rs1544410) was performed using TaqMan
® SNP Genotyping Assay. All patients and controls
had determination of body mass index (BMI), bone mineral density (BMD) and smoking history.
Results: The mean age of patients was 39 ± 10.5 years compared to 38.7 ± 10.7 years of the controls (p = 0.86),
the BMI was 24.8 ± 4.2 kg/m
2 compared to 25.7 ± 4.8 kg/m
2 of the controls (p = 0.23), the BMD in the lumbar
spine 0.981 ± 0.15 compared to 1.025 ± 013 of the controls (p = 0.06) and the total hip BMD was 0.875 ± 0.14
compared to 0.969 ± 0.12 of the controls (p < 0.001). There were no differences of the Taq-I (TT, CT, CC) and Bsm-I
genotypes (GG, GA, AA) and allelic frequencies between MS and control individuals. Multivariate analysis also failed
to show any association of the Taq-I and Bsm-I polymorphisms and MS or sex, BMI, BMD and smoking history.
Conclusions: This study suggests that the Taq-I and Bsm-I polymorphisms of the VDR gene are not associated
with MS risk, BMI or BMD in the Greek population studied.
Background
Multiple sclerosis (MS) is a progressive demyelinating dis-
ease of the central nervous system (CNS) that occurs
mainly in young adults, frequently leading to substantial
disability several years after diagnosis [1]. Vitamin D is
essential for bone and mineral homeostasis and exhibits
immunoregulatory and anti-inflammatory properties [2].
Abnormal regulation of vitamin D metabolism has been
linked to MS and other diseases such as type 1 diabetes,
cancer, and osteoporosis [3-7]. Vitamin D acts through
the vitamin D receptor (VDR) and the membrane asso-
ciated rapid response steroid binding receptor (MARRS)
[8]. Certain polymorphisms of the VDR gene may modify
vitamin D function and metabolism and have been exam-
ined in studies evaluating the role of vitamin D on MS [9].
Several such studies that have investigated the role of
VDR gene polymorphisms in various ethnic groups have
produced conflicting results. A Japanese study reported
an association between the Bsm-I VDR gene allelic poly-
morphism and MS [10]. An Australian MS case-control
study found a significant difference of the Taq-I poly-
morphism genotype distribution in MS patients [11].
Similar results were reported in other studies [12].
Nevertheless, other studies found no differences of a
number of VDR gene polymorphisms between MS and
control groups [13-15]. However, these as well as other
studies reported other associations of the VDR gene poly-
morphisms, such as a significant interaction between
winter sun exposure during childhood [13], or interaction
between dietary intake of vitamin D and VDR gene poly-
morphisms on MS risk [16], and involvement of the Fok-
I VDR gene polymorphism in vitamin D metabolism [14].
In the present study we investigated the Taq-I and Bsm-I
polymorphisms of the VDR gene in a cohort of MS
patients and a control group in Northwest Greece.
Methods
Patients
The individuals recruited in this study were 69 consecu-
tive MS patients referred to the Nuclear Medicine
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as part of a screening program of all MS patients for
osteopenia or osteoporosis, and 81 control individuals
matched for sex and age. All patients satisfied the Mc
Donald criteria for MS diagnosis [17]. None of the case
and control individuals were receiving chronically ster-
oids, bisphosphonates or selective estrogen receptor
modulators. Control individuals consisted of non-family
visitors to hospitalized patients in the neurology and
nuclear medicine services. Patients and control subjects
with a current or past medical condition or medication
use that may influence bone mineral metabolism
(hyperthyroidism, rheumatoid arthritis, hormone repla-
cement therapy, use of oral contraceptives for a period
longer that six months, past or recent use of hormone
therapy, etc.) were excluded from the study. Patients
and controls were asked to give 10 ml of blood for the
study and they signed informed consent for testing. The
research protocol and consent form was approved by
the University Hospital of Ioannina Human Research
Committee.
Scanning
DXA scanning was performed utilizing a Hologic
Discovery W scanner (Hologic, Bedford, MA, United
States). All subjects had DXA scans performed in both
lumbar spine (L1-L4) and left total hip in supine posi-
tion. The scans and data analysis were performed by the
same technician. For data analysis, a software package
(v. 12.3:7, Hologic, Bedford, MA, United States) was
employed as directed by the manufacturer. The mea-
surements included the area of the examined bone, the
bone mineral content (BMC) and the BMD of each
anatomical site.
Genotyping of Taq-I and Bsm-I polymorphisms
All molecular genetic studies were performed in the
Laboratory of Medical Genetics in the Medical School
of the University of Ioannina blinded to case control
status. Genotyping of Taq-I (rs731236) and Bsm-I
(rs1544410) was performed using TaqMan
® SNP Geno-
typing Assay which consists of a predesigned mix of
unlabeled polymerase chain reaction (PCR) primers and
the TaqMan
® minor groove binding group (MGB)
probe (FAM™ and VIC
® dye-labeled). All TaqMan SNP
Genotyping Assays are designed to work with TaqMan
®
Universal PCR MasterMix which contains DNA poly-
merase, dNTPs and optimized mix components and
uses the same thermal conditions. These assays were
purchased from ABI (Applied Biosystems), and they
were applied using a Real Time PCR Rotor-Gene
RG3000 thermocycler (Corbett). The Taq1 T/C poly-
morphism is located in exon 9 that results in a Ile ® Ile
substitution for a silent codon change. It was genotyped
using Real-Time PCR in which one probe labeled with
VIC
® detects the T allele and the other probe labeled
with FAM™ detects the C allele. Similarly, the Bsm1
G/A polymorphism at position 10,583,292 of the chro-
mosomal region 12q12-q14 is located in the intron
between exons 8 and 9 and is without consequences for
the VDR protein structure. This SNP genotyped using
VIC
® labeled probe for the G allele detection and
FAM™ labeled probe for A allele detection, correspond-
ingly. Real Time PCR was performed using 7.5 μl
TaqMan
® Genotyping Master Mix (2×), 0.75 μl
TaqMan
® SNP Genotyping Assay (TaqMan probes)
(20×), 5.75 μl Dnase Free Water and 1 μlD N A
(1-10 ng), to bring the final reaction volume to 15 μl.
The Real Time PCR thermal conditions were as follows:
Initial denaturing at 95°C for 10 min; 40 cycles of 96°C
for 15 sec (denaturing) and 60°C for 1 min (annealing/
extension). Samples were run in duplicates, with posi-
tive, negative controls and blanks. All materials were
used in the TaqMan
® SNP Genotyping Assay (ABI) in
accordance with the manufacturer’s instructions and the
information on the Applied Biosystems web site http://
www.appliedbiosystems.com.
Statistical analysis
Continuous data are presented as mean (standard devia-
tion), categorical data as percentages. For comparisons
of mean values between patients and controls statistical
analysis was performed by the independent samples
t-test. Categorical data was compared using comparison
of two proportions (two-sided). Stepwise multiple
regression analysis was performed to examine factors
independently associated with the Taq-I and Bsm-I
polymorphisms of the VDR gene. Gender, age, body
mass index (BMI), MS diagnosis versus controls, smok-
ing duration and lumbar spine/total hip BMD were
included in the model as independent variables. P < =
0.05 was considered as statistically significant. The soft-
ware used for the statistical analysis was STATISTICA
(Stat Soft, Tulsa, OK).
Results
The physical characteristics of the MS patients and con-
trol group are shown in Table 1. The characteristics are
shown separately for females and males. The various
parameters that were recorded include mean age, BMI,
smoking years, BMD and expanded disability scale score
(EDSS) and MS type for the patients.
The genotypic and allelic frequencies of the Taq-I
(T > C) and Bsm-I (G > A) polymorphisms of the VDR
gene are depicted in table 2. No statistically significant
differences in the proportions of either polymorphism
or allelic frequencies were found between the patient
and the control groups. When the genotypic and allelic
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patient group (relapsing-remitting MS, secondary
progressive MS and primary progressive MS) and con-
trol individuals, no statistically differences were observed
as well (data not shown).
Among the various parameters examined, statistically
significant differences were found only in hip BMD
between patients and control groups (Table 3). There
was also a trend for lower BMD in the lumbar spine of
the patients compared to controls but the result did not
reach statistical significance (p = 0.06).
Multiple linear regression analysis of the Taq-I and
Bsm-I genotypic frequencies showed independence from
MS diagnosis versus controls, age, sex, smoking history,
BMI, and lumbar spine or hip BMD (Table 4).
Discussion
In the present prospective study, we examined the Taq-I
and Bsm-I common polymorphisms of the VDR gene,
near its 3’ untranslated region. Although these poly-
morphisms do not result in structural changes of the
VDR protein, linkage disequilibrium with variation in
the 3’ untranslated region of the VDR gene may result
in altered protein expression [18]. Our results showed
no association between the Taq-I and Bsm-I polymorph-
isms of the VDR gene between the 69 MS patients and
81 control individuals, independently of the MS type.
Previous studies have shown either correlation or no
association suggesting ethnic or regional differences
[1,9]. For example, a Japanese group reported in 77
patients and 95 controls an overrepresentation of the
Bsm-I G allele and homozygote GG in MS patients and
in addition higher frequency of the Apa-I AA genotype
and A allele in MS [10,19]. Similarly, an Australian
case-control study in 104 MS patients and 104 controls,
found a significant difference of genotype distribution
between the case and control groups for the Taq-I poly-
morphism and the allelic frequency [11]. Partridge et al.
in 419 cases and 422 controls described reduced
Table 1 Physical characteristics of the MS patients (females and males) and control group [mean value ± standard
deviation (range)]
Females Males
Characteristics n MS Patients (46) Controls (58) MS Patients (23) Controls (23)
Mean age (years) 38.5 ± 9.9 (21-58) 38.6 ± 10.8 (20-60) 39.5 ± 11.8 (21-60) 38.8 ± 10.5 (23-60)
BMI (kg/m
2) 24.9 ± 4.6 (16.8-34) 24.9 ± 5.1 (18.5-45.7) 25.1 ± 3.7 (17.4-36.4) 27.6 ± 3.2 (21.2-31.9)
Smoking period (years) 9.1 ± 10.8 (0-39) 8 ± 9.8 (0-33) 17 ± 12.4 (0-44) 12.4 ± 12.3 (0-38)
BMD (LS) 0.996 ± 0.16 (0.675-1.329) 1.025 ± 0.135 (0.738-1.29) 0.956 ± 0.12 (0.774-1.215) 1.028 ± 0.13 (0.71-1.26)
BMD (Hip) 0.857 ± 0.14 (0.542-1.132) 0.947 ± 0.123 (0.661-1.244) 0.915 ± 0.14 (0.615-1.286) 1.022 ± 0.1 (0.745-1.191)
EDSS 1.5 ± 1.8 (0 -5.5) 2.76 ± 2.5 (0 - 8)
MS type RRMS = 32 RRMS = 15
SPMS = 13 SPMS = 7
PPMS = 1 PPMS = 1
MS: Multiple sclerosis; BMI: body mass index; EDSS: Expanded disability scale score; BMD: Bone mineral density; LS: Lumbar spine.
Hip: Total hip area; RRMS: Relapsing-remitting MS; SPMS: Secondary progressive MS; PPMS: Primary progressive MS.
Table 2 Comparison between MS patients and control
individuals of the Taq-I (T > C) and Bsm-I (G > A)
polymorphisms of the VDR gene
Enzyme analysis n Patients (69) Controls (81) p
Taq-I polymorphism
Genotype
TT 30 (43.5%) 33 (44.8%) 0.91
CT 30 (43.5%) 36 (44.4%) 0.94
CC 9 (13%) 12 (14.8%) 0.9
Allele
T 65.2% 63% 0.78
C 34.8% 37% 0.80
Bsm-I polymorphism
Genotype
GG 28 (40%) 26 (32%) 0.54
GA 41 (60%) 55 (68%) 0.42
AA 0 0
Allele
G 70% 66% 0.60
A 30% 34% 0.6
MS: Multiple sclerosis; VDR: Vitamin D receptor.
Table 3 Comparison of various parameters between MS
patients and control individuals
Factor Patients Controls p
Sex 46 Female 58 Female
23 Male 23 Male
Mean age (years) 39.0 ± 10.5 38.7 ± 10.7 0.86
BMI (kg/m
2) 24.8 ± 4.2 25.7 ± 4.8 0.23
Smoking period (years) 11.9 ± 11.8 9.3 ± 10.7 0.18
BMD (LS) 0.981 ± 0.15 1.025 ± 0.13 0.06
BMD (Hip) 0.875 ± 0.14 0.969 ± 0.12 <0.001*
BMI: body mass index; BMD: Bone mineral density; LS: Lumbar spine; Hip:
Total hip area.
*: Statistically significant.
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[12]. It is interesting that the above studies that reported
association of VDR gene polymorphisms and MS,
involved populations with possibly high exposure to
vitamin D either due to increased sunlight or higher
intake.
Several large case-control studies have reported no
association of the common VDR gene polymorphisms
and MS risk. Thus, a US study in 214 MS cases and 428
age-matched controls found no associations for any of
the single-nucleotide polymorphisms in VDR, but found
an interaction between dietary intake of vitamin D and
the VDR Fok-I polymorphism on MS risk. Specifically,
individuals with the ff genotype had decreased MS risk
with higher vitamin D intake [16]. Negative results have
been reported in a Canadian study employed restriction
fragment length polymorphisms and highly polymorphic
microsatellite markers to study VDR gene polymorph-
isms and MS risk [15]. Α recent study in 136 MS cases
and 235 controls showed no significant associations
between the polymorphisms Cdx-2, Fok-I, or Taq-I and
MS risk, but there was a significant correlation between
winter sun exposure during childhood, the genotype at
Cdx-2, and MS risk [13]. In that study the G allele was
associated with increased risk of MS in the low sun
exposure group (≤2 hours per day), indicating that an
interaction of the VDR gene polymorphisms and MS
m a yb ed e p e n d e n to np a s ts u ne x p o s u r e[ 1 3 ] .A n o t h e r
study in 212 MS patients and 289 controls found no
association of Apa-I and Taq-I VDR gene polymorph-
isms with the serum levels of 25(OH)D and 1,25(OH)(2)
D, and MS risk [20]. A further study in the same cohort
of patients, although failed to find any association of the
Fok-I VDR gene polymorphism with MS, reported that
the f-allele was associated with lower winter and sum-
mer serum 25(OH)D levels in MS patients and lower 25
(OH)D levels in healthy controls. In addition, the f-allele
carriers had higher 1,25(OH)(2)D/25(OH)D-ratios com-
pared to f-allele carriers, indicating a possible role of the
Fok-I VDR gene polymorphism in vitamin D metabo-
lism [14]. Thus, certain polymorphisms of the VDR
gene may have regulating effects on vitamin D function
and metabolism and may be associated with MS risk,
depending on previous or current vitamin D intake [9].
In the present study there was increased frequency of
low BMD in MS patients compared to controls, espe-
cially involving the hip area and to a lesser degree the
lumbar spine. Our results of low BMD in MS patients
are in accordance with previous studies that demon-
strated reduced BMD and increased frequency of osteo-
porosis in MS associated with low vitamin D levels
[21,22]. However, the multivariate analysis failed to
show any dependence of the low BMD from the Taq-I
and Bsm-I polymorphisms of the VDR gene. Previous
studies have showed no evidence of association between
common polymorphisms of the VDR gene and BMD in
British women [23], and between the Bsm-I VDR gene
polymorphism and osteoporosis in a Korean population
[24]. However, VDR gene polymorphisms have been
associated with Graves’ disease in a Japanese population
[25], and has been suggested that a Fok-I VDR gene
polymorphism may predict risk of osteoporosis in such
patients [26].
Conclusions
In summary, our findings showed no direct association
of the Taq-I and Bsm-I polymorphisms of the VDR
gene with either MS risk or bone mineral density in a
sample population of Northwest Greece. Future studies
should focus on the possible regulatory role of such
polymorphisms on vitamin D function and metabolism
and assess the MS risk depending on long term sunlight
exposure and vitamin D intake.
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